BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 23567481)

  • 1. Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients.
    Mann RM; Bult P; van Laarhoven HW; Span PN; Schlooz M; Veltman J; Hoogerbrugge N
    Eur J Radiol; 2013 Sep; 82(9):1416-22. PubMed ID: 23567481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast fine-needle aspiration cytology performance in the high-risk screening population: a study of BRCA1/BRCA2 mutation carriers.
    Georgieva RD; Obdeijn IM; Jager A; Hooning MJ; Tilanus-Linthorst MM; van Deurzen CH
    Cancer Cytopathol; 2013 Oct; 121(10):561-7. PubMed ID: 23720450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
    J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach.
    Granader EJ; Dwamena B; Carlos RC
    Acad Radiol; 2008 Dec; 15(12):1590-5. PubMed ID: 19000876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
    Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
    Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling.
    Nicoletto MO; Donach M; De Nicolo A; Artioli G; Banna G; Monfardini S
    Cancer Treat Rev; 2001 Oct; 27(5):295-304. PubMed ID: 11871866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total skin-sparing mastectomy in BRCA mutation carriers.
    Peled AW; Irwin CS; Hwang ES; Ewing CA; Alvarado M; Esserman LJ
    Ann Surg Oncol; 2014 Jan; 21(1):37-41. PubMed ID: 23982256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Lynch HT; Ghadirian P; Tung N; Kim-Sing C; Olopade OI; Domchek S; Eisen A; Foulkes WD; Rosen B; Vesprini D; Sun P; Narod SA
    Breast Cancer Res Treat; 2011 May; 127(1):287-96. PubMed ID: 21221768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
    Obdeijn IM; Winter-Warnars GA; Mann RM; Hooning MJ; Hunink MG; Tilanus-Linthorst MM
    Breast Cancer Res Treat; 2014 Apr; 144(3):577-82. PubMed ID: 24567197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; Blom J; Huijskens E; Jager A; van den Ouweland A; van Geel B; Hooning MJ; Brekelmans CT; Klijn JG
    J Clin Oncol; 2009 Aug; 27(23):3764-71. PubMed ID: 19564533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.
    Hudelist G; Wagner T; Rosner M; Fink-Retter A; Gschwantler-Kaulich D; Czerwenka K; Kroiss R; Tea M; Pischinger K; Köstler WJ; Attems J; Mueller R; Blaukopf C; Kubista E; Hengstschläger M; Singer CF
    Endocr Relat Cancer; 2007 Dec; 14(4):1053-62. PubMed ID: 18045956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast magnetic resonance imaging for screening high-risk women.
    Sung JS; Dershaw DD
    Magn Reson Imaging Clin N Am; 2013 Aug; 21(3):509-17. PubMed ID: 23928241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
    Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
    J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series.
    Hagen AI; Kvistad KA; Maehle L; Holmen MM; Aase H; Styr B; Vabø A; Apold J; Skaane P; Møller P
    Breast; 2007 Aug; 16(4):367-74. PubMed ID: 17317184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
    Zuradelli M; Peissel B; Manoukian S; Zaffaroni D; Barile M; Pensotti V; Cavallari U; Masci G; Mariette F; Benski AC; Santoro A; Radice P
    Breast Cancer Res Treat; 2010 Nov; 124(1):251-8. PubMed ID: 20373018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Background Parenchymal Enhancement and Lesion Kinetics in Breast MRI of BRCA 1/2 Mutation Carriers Compared to Matched Controls Using Quantitative Kinetic Analysis.
    Lewin AA; Kim SG; Babb JS; Melsaether AN; McKellop J; Moccaldi M; Klautau Leite AP; Moy L
    Acad Radiol; 2016 Mar; 23(3):358-67. PubMed ID: 26774741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.
    Huszno J; Budryk M; Kołosza Z; Nowara E
    Oncology; 2013; 85(5):278-82. PubMed ID: 24217135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.